Latest Conference Articles

Treatment with axicabtagene ciloleucel in the second-line setting led to significant improvement in overall survival compared with high-dose therapy plus transplant in patients with early relapsed or refractory large B-cell lymphoma.

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

The investigational agent, ABBV-011, is showing promise, according to results from a phase 1 clinical trial.

According to Binod Dhakal, MD, ciltacabtagene autoleucel may become a new standard therapy for patients with lenalidomide (Revlimid)-refractory multiple myeloma.

Lasofoxifene in combination abemaciclib showed antitumor activity that was not compromised by co-occuring alterations that confer endocrine resistance.

A sustained overall survival benefit has been reported from the phase 3 TROPiCS-02 study.

The combination of doxorubicin, balstilimab, and zalifrelimab has some early signals of activity in both immune hot and cold sarcoma subtypes with manageable toxicity.

The primary end point was not reached in the phase 3 SOLSTICE study.

Patritumab deruxtecan treatment yielded efficacy results and was safe for patients with metastatic breast cancer.

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

Correlative work is ongoing following positive results from the phase 1 study of cabozantinib with nivolumab and ipilimumab.

In a phase 1 study, anti-tumor responses were induced with PRT811 treatment in patients with recurrent, high-grade glioma and advanced or metastatic uveal melanoma.

Sara Tolaney, MD, MPH, discusses sacituzumab govitecan-hziy as an effective and safe treatment for patients with hormone receptor-positive/HER2-negative metastatic breast cancer.

Data from CheckMate 9LA trial further support the use of nivolumab plus ipilimumab and chemotherapy as an efficacious first-line treatment option for patients with metastatic NSCLC, says David P. Carbone, MD, PhD.

New data show the promise for use of tovorafenib to reduce pre-treated pediatric patients with a low-grade glioma.

In the combination of fianlimab and cemiplimab, we showed a consistent and reproducible high clinical activity in 3 independent cohorts of patients who were naive to anti–PD-1 in the advanced melanoma setting, says Omid Hamid, MD.

Patients with non–small cell lung cancer who completed definitive surgery saw clinical benefits after being treated with neoadjuvant nivolumab and chemotherapy.

New findings with the gamma secretase inhibitor nirogacestat show pain reduction for patients with desmoid tumors.

Preliminary results from the phase 1/2 ARTEMIDE-01 trial show the potential for PD-1 and TIGIT bispecific agent rilvegostomig in patients with advanced or metastatic PD-L1–positive non–small cell lung cancer.

Results from the DESTINY-CRC02 study showed that a lower dose of trastuzumab deruxtecan elicited promising results for patients with HER2-positive metastatic colorectal cancer vs a higher dose of the therapy.

New patient reported outcomes from the phase 3 RUBY trial show patients with primary advanced or recurrent endometrial cancer maintained their health-related quality of life when on dostarlimab and chemotherapy.

Results from the TALAPRO-2 study highlight the potential for the first-line treatment of patients with homologous recombination repair altered metastatic castration-resistant prostate cancer.

When comparing patients with metastatic castration-resistant prostate cancer who have homologous recombination repair deficiency mutations, those with BRCA mutations have worse outcomes compared to patients without the BRCA mutation in their disease.

Promising results reported from a study of GC012F in patients with relapsed or refractory multiple myeloma, warrant further research.

Katherine B. Peters, MD, PhD, discusses the findings from the phase 3 INDIGO trial which were presented at the 2023 ASCO annual meeting.

The results of vorasidenib signal potential for the agent to become the first targeted therapy in low-grade glioma.

The same high cure rates achieved with preoperative chemoradiation can be achieved with preoperative FOLFOX, according to Deb Schrag, MD, FASCO, MPH.

Kathleen N. Moore, MD says the phase 3 MIRASOL results bring a new standard-of-care to the FRα-high, platinum-resistant ovarian cancer landscape.

Pooled findings from MagnetisMM studies show the elranatamab has early activity in relapsed or refractory multiple myeloma.